Technical aspects of predictive and prognostic markers in breast cancer

What UK NEQAS data shows

Keith Miller, Merdol Ibrahim, Sarah Barnett, Bharat Jasani

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Predictive and prognostic testing for breast cancer is now an important part of cellular pathology. The UK National External Quality Assessment Scheme (NEQAS) for immunocytochemistry and fluorescent in situ hybridization plays a significant role in ensuring that the quality of testing meets the clinical standards required, by assessing the performance of each participant laboratory every 3 months. Besides receiving a confidential performance report, data on the methods used are collected, analysed against the scores and published in the UK NEQAS journal. This information is intended to help those who are not achieving the best scores to improve their performance.

Original languageEnglish
Pages (from-to)135-149
Number of pages15
JournalCurrent Diagnostic Pathology
Volume13
Issue number2
DOIs
Publication statusPublished - Apr 2007
Externally publishedYes

Fingerprint

Fluorescence In Situ Hybridization
Immunohistochemistry
Pathology
Breast Neoplasms

Keywords

  • Breast cancer
  • External quality assessment
  • HER-2
  • Immunocytochemistry
  • Immunohistochemistry
  • Oestrogen receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Technical aspects of predictive and prognostic markers in breast cancer : What UK NEQAS data shows. / Miller, Keith; Ibrahim, Merdol; Barnett, Sarah; Jasani, Bharat.

In: Current Diagnostic Pathology, Vol. 13, No. 2, 04.2007, p. 135-149.

Research output: Contribution to journalArticle

Miller, Keith ; Ibrahim, Merdol ; Barnett, Sarah ; Jasani, Bharat. / Technical aspects of predictive and prognostic markers in breast cancer : What UK NEQAS data shows. In: Current Diagnostic Pathology. 2007 ; Vol. 13, No. 2. pp. 135-149.
@article{44ff451ceead44cc929945a2ff1b5593,
title = "Technical aspects of predictive and prognostic markers in breast cancer: What UK NEQAS data shows",
abstract = "Predictive and prognostic testing for breast cancer is now an important part of cellular pathology. The UK National External Quality Assessment Scheme (NEQAS) for immunocytochemistry and fluorescent in situ hybridization plays a significant role in ensuring that the quality of testing meets the clinical standards required, by assessing the performance of each participant laboratory every 3 months. Besides receiving a confidential performance report, data on the methods used are collected, analysed against the scores and published in the UK NEQAS journal. This information is intended to help those who are not achieving the best scores to improve their performance.",
keywords = "Breast cancer, External quality assessment, HER-2, Immunocytochemistry, Immunohistochemistry, Oestrogen receptor",
author = "Keith Miller and Merdol Ibrahim and Sarah Barnett and Bharat Jasani",
year = "2007",
month = "4",
doi = "10.1016/j.cdip.2006.12.003",
language = "English",
volume = "13",
pages = "135--149",
journal = "Diagnostic Histopathology",
issn = "1756-2317",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Technical aspects of predictive and prognostic markers in breast cancer

T2 - What UK NEQAS data shows

AU - Miller, Keith

AU - Ibrahim, Merdol

AU - Barnett, Sarah

AU - Jasani, Bharat

PY - 2007/4

Y1 - 2007/4

N2 - Predictive and prognostic testing for breast cancer is now an important part of cellular pathology. The UK National External Quality Assessment Scheme (NEQAS) for immunocytochemistry and fluorescent in situ hybridization plays a significant role in ensuring that the quality of testing meets the clinical standards required, by assessing the performance of each participant laboratory every 3 months. Besides receiving a confidential performance report, data on the methods used are collected, analysed against the scores and published in the UK NEQAS journal. This information is intended to help those who are not achieving the best scores to improve their performance.

AB - Predictive and prognostic testing for breast cancer is now an important part of cellular pathology. The UK National External Quality Assessment Scheme (NEQAS) for immunocytochemistry and fluorescent in situ hybridization plays a significant role in ensuring that the quality of testing meets the clinical standards required, by assessing the performance of each participant laboratory every 3 months. Besides receiving a confidential performance report, data on the methods used are collected, analysed against the scores and published in the UK NEQAS journal. This information is intended to help those who are not achieving the best scores to improve their performance.

KW - Breast cancer

KW - External quality assessment

KW - HER-2

KW - Immunocytochemistry

KW - Immunohistochemistry

KW - Oestrogen receptor

UR - http://www.scopus.com/inward/record.url?scp=34047112458&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047112458&partnerID=8YFLogxK

U2 - 10.1016/j.cdip.2006.12.003

DO - 10.1016/j.cdip.2006.12.003

M3 - Article

VL - 13

SP - 135

EP - 149

JO - Diagnostic Histopathology

JF - Diagnostic Histopathology

SN - 1756-2317

IS - 2

ER -